You are viewing the comprehensive archive for articles tagged with "eli lilly." Our editorial team delivers timely artificial intelligence coverage, practical insights, and industry-focused analysis across the topics shaping how AI is built, funded, regulated, and adopted. This section brings together the most relevant news, research, and expert commentary to help you understand trends and make better technology decisions. Stay informed with AIstify to keep your perspective current and complete.
Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally.
NVIDIA and Eli Lilly are creating a $1 billion AI co-innovation lab to accelerate drug discovery. The lab will integrate AI, biomedical data, and robotics to transform medicine development.